Study Shows Nerve Ablation Slows Pancreatic Cancer Metastasis
Autonomix Medical, Inc. has announced significant findings from a preclinical animal study that evaluated the effects of targeted nerve ablation on tumor metastases and growth. The Texas-based medical device company, traded on NASDAQ under the ticker symbol AMIX, focuses on innovative technologies for diagnosing and treating nervous system-related diseases.
The study involved two groups of mice that were implanted with human pancreatic tumor cells. The experimental group received peri-pancreatic neural ablation through ethanol infusion, while the control group did not receive any treatment. Results indicated that targeted nerve ablation led to a statistically significant reduction in both tumor mass growth and metastases. Specifically, the experimental group showed a 60% reduction in local invasion and a 40% reduction in liver metastases compared to the control group.
Lori Bisson, CEO of Autonomix, noted that these encouraging preclinical results support existing literature suggesting that neural pathways play a crucial role in the spread and growth of cancer cells. Bisson emphasized that even with a small sample size, the data showed significant reductions in metastasis, thus validating the potential of targeted nerve ablation in impacting pancreatic cancer progression. She mentioned that the current focus is on pain reduction for pancreatic cancer patients, but future studies will explore the application of this technology in slowing cancer growth and spread in humans.
Autonomix’s technology platform features a catheter-based microchip sensing array that can detect and differentiate neural signals with remarkable sensitivity, purportedly 3,000 times more sensitive than existing technologies. This capability promises to revolutionize the diagnosis and treatment of peripheral nervous system diseases across various parts of the body. The company is initially targeting pancreatic cancer-related pain, addressing a critical need for more effective treatment options beyond traditional opioids or invasive ethanol injections, which often come with severe side effects.
The company envisions its technology platform as a versatile tool that can address a wide range of medical conditions, including chronic pain, hypertension, and cardiac issues. Autonomix aims to improve clinical outcomes by offering a safer and more accurate method for nerve ablation compared to current practices that may cause collateral damage due to their lack of precision.
In summary, Autonomix Medical, Inc. has made a significant step forward in demonstrating the potential of their nerve ablation technology in reducing tumor metastasis and growth in pancreatic cancer. The next phase will involve translating these preclinical findings into clinical applications, with the hope of offering new avenues for treatment that could significantly improve patient outcomes in the future.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
